OCT 12, 2017 12:00 PM PDT

Live-single-cell phenotypic biomarkers measured from primary biopsy samples: An emerging class of biomarkers toward the development of precision diagnostics and the discovery and development

  • Co-Founder and CEO, Cellanyx
      As CEO of Cellanyx, Ashok is commercializing a biopsy-on-a-chip platform technology that enables precision diagnostics and personalized therapeutics for prostate and breast cancers.

      Cellanyx is leveraging the unique capability to rapidly analyze live patient-biopsy-cells on an ex vivo platform powered by microfluidics, phenotypic biomarkers, machine vision, and machine learning.

      Cellanyx's first-in-class platform is poised to dramatically disrupt the diagnostics and therapeutic tools markets that historically have been limited by static formalin-fixed cells, bulk and noisy genomic analysis, irrelevant cell line cultures and cumbersome animal models.

      Ashok developed Cellanyx's core technology during an academic career researching topics including multidrug resistance and matrix-biology. A Fellow of Startup Leadership Boston, Ashok combines his background in biophysics with expertise in business on project management, operations, team development, entrepreneurship and raising capital.

      Passionate about translating basic scientific discoveries into therapeutic gains, and engaged in oncology research since 1996, Ashok is exceptionally motivated to create meaningful value for patients, physicians, payers, and investors.

      Ashok enjoys collaborating with executives, clinicians, engineers, and scientists to advance our understanding of biological processes, promote discovery, develop clinically actionable technologies, and create sustainable clinical and therapeutic value.

      Ashok began his scientific training at the National Institutes of Health (NIH). Advised by two Nobel Laureates, Ashok received his S.B. in Biology from MIT and Ph.D. from Columbia University. Raised in Potomac, Maryland, Ashok is a lifelong tennis player and new father, appreciating their respective emphases on preparation, dedication, stamina, and good hands.


    The promise of precision and personalized medicine is rooted in accurate, highly sensitive, and specific disease biomarkers. This is particularly true for cancer-a disease characterized by marked tumor heterogeneity and diverse molecular signatures. Although thousands of biomarkers have been described, only a very small number have been successfully translated into clinical use. Undoubtedly, there is need for rapid, quantitative, and more cost effective biomarkers for tumor diagnosis and prognosis, to allow for better risk stratification and aid clinicians in making personalized treatment decisions.

    Show Resources
    Show Resources